Estudo randomizado | Transtuzumab Deruxtecan vs. trastuzumabe Entansina para câncer de mama.

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Trastuzumab Deruxtecan Ups PFS in HER2+ Metastatic Breast Cancer – HealthDay

Comentário no Twitter

In patients with metastatic HER2+ breast cancer that progressed after primary therapy, treatment with trastuzumab deruxtecan resulted in a higher response rate and longer progression-free survival than trastuzumab emtansine. https://t.co/R5suUeMLgE pic.twitter.com/yMiGrJw71U

— NEJM (@NEJM) March 24, 2022